IP Library Patent Application 16863948
Patent Application
App. No. 16/863,948

FC SILENCED ANTIBODY DRUG CONJUGATES (ADCS) AND USES THEREOF

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
16/863,948
Abstract

Disclosed are antibodies and antibody drug conjugates having an Fc region with substitutions resulting in essentially a silent Fc region. The antibodies and antibody drug conjugates described herein are useful for the depletion of cells and for the treatment of various hematopoietic diseases, metabolic disorders, cancers, e.g., acute myeloid leukemia (AML) and autoimmune diseases, among others. The compositions and methods described herein can be used to treat a disorder directly, for instance, by depleting, e.g., a population of CD45+ or CD117+ cancer cells or CD45+ autoimmune cells. The compositions and methods described herein can also be used to prepare a patient for hematopoietic stem cell transplant therapy and to improve the engraftment of hematopoietic stem cell transplants by selectively depleting endogenous hematopoietic stem cells prior to the transplant procedure.

Claims (6)

1 . An antibody, or antigen-binding portion thereof, comprising an Fc region, wherein the Fc region comprises amino acid substitutions consisting essentially of amino acid substitutions L234A, L235A, and D265C (EU index.

2 . An antibody, or antigen-binding portion thereof, comprising an Fc region, wherein the Fc region comprises amino acid substitutions consisting essentially of amino acid substitutions L234A, L235A, S239C and D265A (EU index).

3 . An antibody, or antigen-binding portion thereof, comprising an Fc region, wherein the Fc region comprises amino acid substitutions consisting essentially of amino acid substitutions H435A, L234A, L235A, and D265C (EU index).

4 . The antibody, or antigen-binding portion of claim 1 , wherein the antibody, or the antigen-binding region, is conjugated to a cytotoxin.

5 . The antibody, or antigen-binding portion of claim 2 , wherein the antibody, or the antigen-binding region, is conjugated to a cytotoxin.

6 . The antibody, or antigen-binding portion of claim 3 , wherein the antibody, or the antigen-binding region, is conjugated to a cytotoxin.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 22, 2025
From: VOR BIOPHARMA, INC.
To: REGENERON PHARMACEUTICALS, INC.
Reel/Frame 074028/0972 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 26, 2023
From: MAGENTA THERAPEUTICS, INC.
To: VOR BIOPHARMA, INC.
Reel/Frame 064393/0570 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 16, 2023
From: PALCHAUDHURI, RAHUL; BOITANO, ANTHONY; COOKE, MICHAEL; MCDONAGH, CHARLOTTE FENTON; PEARSE, BRADLEY R.; SARMA, GANAPATHY N.
To: MAGENTA THERAPEUTICS, INC.
Reel/Frame 062726/0446 →